Pantoprazole Almus (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazole Almus, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazole Almus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Almus is a proton pump inhibitor that acts on the acid‑secreting pathway of the stomach. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining. - Erosive oesophagitis: accelerates healing of erosive lesions. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild and transient. - Diarrhea: usually self‑limiting. - Nausea: occasional mild discomfort. - Abdominal pain: mild cramping. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: kidney inflammation. - Severe hypersensitivity: rash, angioedema, anaphylaxis. - Osteoporosis‑related fractures: long‑term use risk. - Low magnesium levels (hypomagnesemia): may cause muscle cramps or arrhythmia.

Before prescribing Pantoprazole Almus, consider the following safety points: - Assess renal function: dose adjustment may be required in severe impairment. - Review hepatic status: use with caution in moderate liver disease. - Evaluate long‑term use: monitor for bone density loss and magnesium levels. - Pregnancy and lactation: weigh benefits against potential risks; consult guidelines. - Drug‑interaction review: check concomitant medications for known interactions. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole may affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption may lower efficacy. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma levels. - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation. - Digoxin: possible rise in serum concentration. - Methotrexate: reduced renal clearance may raise toxicity risk.